Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advances study identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://orlandoc121iov8.ja-blog.com/profile